These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 20065126)
1. Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease. Brodsky MA; Park BS; Nutt JG Arch Neurol; 2010 Jan; 67(1):27-32. PubMed ID: 20065126 [TBL] [Abstract][Full Text] [Related]
2. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Nutt JG; Carter JH; Carlson NE Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease. Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N; Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739 [TBL] [Abstract][Full Text] [Related]
4. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. Parkinson Study Group JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889 [TBL] [Abstract][Full Text] [Related]
5. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Parkinson Study Group CALM Cohort Investigators Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655 [TBL] [Abstract][Full Text] [Related]
6. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release. Rascol O Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197 [TBL] [Abstract][Full Text] [Related]
7. Switching from pergolide to pramipexole in patients with Parkinson's disease. Hanna PA; Ratkos L; Ondo WG; Jankovic J J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747 [TBL] [Abstract][Full Text] [Related]
8. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447 [TBL] [Abstract][Full Text] [Related]
9. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A; Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734 [TBL] [Abstract][Full Text] [Related]
10. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Parkinson Study Group JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527 [TBL] [Abstract][Full Text] [Related]
12. Interactions between deep brain stimulation and levodopa in Parkinson's disease. Nutt JG; Rufener SL; Carter JH; Anderson VC; Pahwa R; Hammerstad JP; Burchiel KJ Neurology; 2001 Nov; 57(10):1835-42. PubMed ID: 11723273 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306 [TBL] [Abstract][Full Text] [Related]
14. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Inzelberg R; Schechtman E; Nisipeanu P Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891 [TBL] [Abstract][Full Text] [Related]
15. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Clarke C E; Speller J M; Clarke J A Cochrane Database Syst Rev; 2000; 2000(3):CD002259. PubMed ID: 10908539 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Poewe WH; Rascol O; Quinn N; Tolosa E; Oertel WH; Martignoni E; Rupp M; Boroojerdi B; Lancet Neurol; 2007 Jun; 6(6):513-20. PubMed ID: 17509486 [TBL] [Abstract][Full Text] [Related]
17. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823 [TBL] [Abstract][Full Text] [Related]
18. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease. Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133 [TBL] [Abstract][Full Text] [Related]
19. [High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero]. Arnold G; Kupsch A Nervenarzt; 1999 Aug; 70(8):742-4. PubMed ID: 10483575 [TBL] [Abstract][Full Text] [Related]
20. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Kulisevsky J; Pagonabarraga J Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]